



**Chelsea and Westminster Hospital NHS Foundation Trust
Trust Medicines Group**

Summary of Main Points from the Meeting held on Monday 26th April 2022

2. Minutes and Summary Notes from last meeting

On account of the Trust response to the Covid-19 Pandemic, this meeting was held via Teams. The minutes and summary notes of the Medicines Group Meeting held on 28th February 2022 were approved. The summary notes will be disseminated and published on the Trust intranet. A quarterly summary report will be drafted and forwarded to the Trust Patient Safety Group meeting for inclusion on the agenda in due course.

3. Matters Arising

The Group noted the matters arising from the previous meeting.

4. Business to be transacted by the Medicines Group

a) Formulary Applications

Full Applications

- **Declaration of conflicts of interest by Group members**
Declaration of any conflicts of interest by any Group members

- **Formulary applications**

Full Applications

Nil

Ex-panel

- **Trurapi 100units/ml vials, Cartridges and Solostar pre-filled pen Insulin (Biosimilar to Insulin Aspart)**

Requested by Diabetology Team for switchover/initiation. Trurapi[®] is the first biosimilar rapid acting insulin analogue that is cost effective. Trurapi[®] is indicated for the treatment of diabetes mellitus in adults, adolescents, and children aged 1 year and above. Its use will be for newly diagnosed patients.

The use of biosimilar is estimated to save the NHS about £300m per annum. Trurapi[®] was added to the NWLIF on the 5th October 2021. Available forms are cartridges, pre-filled pens and vials.

Overall cost saving for the Trust - Trurapi[®] is 30% cheaper therefore leading to a proposed annual cost savings across both hospital sites of £6,370.

Outcome: Approved for addition to the formulary

- **SyreniRing[®] (Etonogestrel / Ethinlyestradiol 0.12mg/0.015 mg per 24 hours) Vaginal Delivery System**

Request from GUM for SyreniRing[®] (Etonogestrel / Ethinlyestradiol 0.12mg/0.015mg per 24 hours) Vaginal Delivery System to be added to the formulary in place of NuvaRing[®] (Etonogestrel 0.12mg/0.015mg per 24 hours) Vaginal Delivery System).

SyreniRing[®] at present offers a cost saving over Nuvaring[®] of £5.94 per unit non-inclusive of any discounted contract pricing. Past annual usage in GUM clinics suggest an annual saving of approximately £2,000 based on 2019 usage statistics.

The principal advantage of over the use SyreniRing[®] is that unlike the formulation currently on formulary (Nuvaring[®]), it is not required to be stored in the refrigerator and has a longer shelf life at room temperature (2



years compared to 4 months). This opens up the possibility of increasing supplies to patients at each visit, reducing the visit frequency. The SyreniRing® formulation is identical to Nuvaring® in terms of the dose, frequency, licenced indication and dimensions of the delivery system.

As the different branded products are interchangeable, it was agreed that the formulary is updated to include only the generic name and that the most cost effective branded product would be procured through Pharmacy.

Outcome: Approved for addition to the formulary

Removals

- Nil

NICE Approved drug applications

- **NICE TA127 - Natalizumab for the treatment of adults with highly active relapsing–remitting multiple sclerosis**

Published by NICE on 22/08/2007

Outcome: Approved for addition to the formulary

- **NICE TA312 - Alemtuzumab for treating highly active relapsing remitting multiple sclerosis**

Published by NICE on 28/05/2014

Outcome: Approved for addition to the formulary

- **NICE TA585 - Ocrelizumab for treating primary progressive multiple sclerosis**

Published by NICE on 12/06/2019

Outcome: Approved for addition to the formulary

- **NICE TA616 - Cladribine for treating relapsing–remitting multiple sclerosis**

Published by NICE on 19/12/2019

Outcome: Approved for addition to the formulary

- **NICE 656 - Siponimod for treating secondary progressive multiple sclerosis**

Published by NICE on 18/11/2020

Outcome: Approved for addition to the formulary

- **NICE TA699 - Ofatumumab for treating relapsing multiple sclerosis**

Published by NICE on 19/05/2021

Outcome: Approved for addition to the formulary

- **NICE TA767 - Ponesimod for treating relapsing–remitting multiple sclerosis**

Published by NICE on 02/02/2022

The above NICE TAs are being approved retrospectively for prescribing in CWFT following the signing of a SLA with Imperial College Healthcare NHS Trust for the provision of Neurology Services

Outcome: Approved for addition to the formulary

- **NICE TA757 - Cabotegravir and Rilpivirine (Enclosure 13a-c) (Approved by HIV/GUM Medicines Sub-Group Meeting - For noting**

Published by NICE on 05/01/2022

Outcome: Approval for addition to the formulary noted

- **NICE TA760 - Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer**

Published by NICE on 12/01/2022

Outcome: Approved for addition to the formulary



Pharmacoeconomic Board requests

Tocilizumab for Anti-GAD antibody syndrome with Stiff Person Syndrome and Temporal Lobe Epilepsy

- Approved by the Pharmacoeconomic Board on 08/12/2021
- IFR - To be submitted once noted at TMG
- IFR Outcome: Awaiting
- For noting

Outcome: Noted

Siltuximab treatment of a patient with idiopathic Multicentric Castleman's Disease

- Approved by the Pharmacoeconomic Board on 05/04/2022
- IFR - To be submitted
- IFR Outcome: Awaiting
- For noting

Outcome: Noted

Other requests

- **Alpelisib (Piqray®) - FOC Scheme Novartis - Metastatic Breast Cancer with a PIK3CA mutation**

Request for Oncology - Alpelisib for treatment of a patient with metastatic breast cancer with a PIK3CA mutation on FOC Scheme

Decision: Noted

4.2 Trust Medicines Policy

- **TMP Section: 30 - Supply of Over-labelled/Pre-packed medicines from Wards/Departments/Out-patient clinics**

Updated to include the following as a clinical areas that can operate in line with this policy:

- Mercury Ward
- Neptune/Jupiter Ward
- Paediatric HDU (Apollo)
- ARC Hounslow
- Feltham Centre for Health
- First Care Practice
- Little Park Surgery

Outcome: Approved

4.3 Medicines Optimisation

- **Guideline for Pharmacy and medical staff managing patient on Clozapine (WMUH Site)**

Guideline for Pharmacy and medical staff managing patient on Clozapine for use at the WMUH site only.

Outcome: Approved

- **Trust Medicines Optimisation Annual Report**

Medicines optimisation encompasses a range of activities intended to improve the way that medicines are selected, procured, prescribed, dispensed and administered.

This report summarises the activities of groups responsible for the management of medicines at Chelsea and Westminster Hospital NHS Foundation Trust, describes developments throughout the 2020-21 year and reports on results of external assessments.

Outcome: Noted

4.4 NICE Technical Appraisals and Guidance

- a) **NICE Technology Appraisals published in February to March 2022**

11 appraisals published in February 2022



TA762 - Olaparib for treating BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy

Recommendation
(Terminated appraisal)
Formulary status / Action
Nil Action

TA763 - Daratumumab in combination for untreated multiple myeloma when a stem cell transplant is suitable

Formulary status / Action
Already included on formulary
Numbers likely to treat at CWH site: 10 patients per year
Numbers likely to treat at WMUH site: 8-10 patients per year
Action: Update formulary accordingly

TA764 - Fremanezumab for preventing migraine

Formulary status / Action
Already included on formulary in line with NICE TA631: Fremanezumab for preventing migraine
Action: Update formulary accordingly

TA765 - Venetoclax with azacitidine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable

Formulary status / Action
Already included on formulary
Action: Update formulary accordingly

TA766 - Pembrolizumab for adjuvant treatment of completely resected stage 3 Melanoma

Recommendation
Formulary status / Action
Already included on formulary
Action: Update formulary accordingly

TA767 - Ponesimod for treating relapsing–remitting Multiple Sclerosis

Formulary status / Action
Not include on the formulary
Application form received - See section 4.1

TA768 - Upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDs

Formulary status / Action
Action:
To confirm numbers likely to treat under this NICE TA

TA769 - Palforzia for treating peanut allergy in children and young people

Recommendation
Formulary status / Action
Action:
To confirm commissioning status
To confirm numbers likely to treat under this NICE TA



TA770 - Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer

Formulary status / Action

Currently included on formulary.

Action: Update formulary accordingly

TA771 - Daratumumab with bortezomib, melphalan and prednisone for untreated Multiple Myeloma Recommendation

(Terminated appraisal)

Formulary status / Action

Action - Nil

TA772 - Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after stem cell transplant or at least 2 previous therapies

Formulary status / Action

Currently included on formulary.

Action: Update formulary accordingly

7 appraisals published in March 2022

TA773 - Empagliflozin for treating chronic heart failure with reduced ejection fraction

Formulary status / Action

To confirm numbers likely to treat under this NICE TA

TA774 - Lenalidomide for relapsed or refractory Mantle Cell Lymphoma Recommendation

(Terminated appraisal)

Formulary status / Action

Nil Action

TA775 - Dapagliflozin for treating chronic kidney disease

Formulary status / Action

To confirm numbers likely to treat under this NICE TA

TA776 - Pitolisant hydrochloride for treating excessive daytime sleepiness caused by obstructive sleep apnoea

Formulary status / Action

Action: Nil - Not recommended

TA777 - Solriamfetol for treating excessive daytime sleepiness caused by obstructive sleep apnoea

Formulary status / Action

Action: Nil - Not recommended

TA778 - Pegcetacoplan for treating paroxysmal nocturnal haemoglobinuria

Formulary status / Action

Not commissioned to treat this condition at CWFT

TA779 - Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency



Formulary status / Action

Not commissioned to treat this condition at CWFT

b) NICE Highly Specialised Technology Appraisals published since last meeting

HST17 - Odevixibat for treating progressive familial intrahepatic cholestasis

Formulary status / Action

Action: Nil - CWFT is not a commissioned site for treating under this NICE TA

4.5 IVIG requests

• IVIG Issues for January 2022 - CW Site

There were 12 IVIG issues in January 2022, with 7 new requests:

Outcome: Noted

• IVIG Issues for January 2022 - WMUH Site

There were 10 IVIG issues in January 2022, with 5 new requests

Outcome: Noted

• IVIG issues for February 2022 - CWH Site

There were 8 IVIG issues in February 2022, with 5 new requests:

Outcome: Noted

• IVIG issues for February 2022- CWH Site

There were 7 IVIG issues in February 2022, with 2 new requests:

Outcome: Noted

4.6 Items for noting

• Quarterly Controlled Drug Summary Report - Q3 2021/22

Quarterly Controlled Drug Summary Report for Q3 2021/22

Outcome: Noted

• Quarterly Controlled Drugs Accountable Officer Report - Q3 2021/22

Quarterly CD Accountable Officer Report for Q3 2021/22

Outcome: Noted

• TMG Report for noting at Patient Safety Group - March 2022

Trust Medicines Group Report for noting at Patient Safety Group - March 2022

Outcome: Noted

• Medication Safety Bulletin - 'Look Alike' and 'Sound Alike' (LASA) Medicines

Medication Safety Bulletin relating to 'Look Alike' and 'Sound Alike' medicines

Outcome: Noted

• Medication Safety Bulletin: Lessons learned from a serious incident - Magnesium Sulfate

Medication Safety Bulletin relating to Lessons learned: Magnesium Sulfate

Outcome: Noted

• Medication Safety Group - Terms of Reference

- Update to chair members

- Update to MSG objective to state that process and system changes to be supported will include use and design of EPR processes and function

- Non-medical prescriber representative to be added to mandated MSG membership list (and not by invite only), and junior doctors to be moved to non-mandated membership list

- Update to quorum requirements to include clinical representation from divisions



Outcome: Noted

- **MHRA Drug Safety Update - March 2022**

MHRA update for March 2022

Outcome: Noted

4.7 Meeting minutes for noting

- **NWLIF NDP Meeting minutes - February 2022**

Minutes from NWLIF NDP Meeting held February 2022

Outcome: Noted

- **Medication Safety Group meeting minutes - March 2022**

Minutes from Medical Safety Group meeting held March 2022

Outcome: Noted

- **HIV/GUM Medicines Sub-Group Meeting - March 2022**

Minutes from HIV/GUM Medicines Sub-Group Meeting held March 2022

Outcome: Noted

- **Chemotherapy Service Group meeting minutes - April 2022**

Minutes from Chemotherapy Service Group meeting held April 2022

Outcome: Noted

5. Any other business

- Nil

6. Date of next meeting

Next meeting

Date: July 2022 - TBC

Time: 8am-9am

Location: via Teams